FDA Pediatric Exclusivity Granted in 2024
The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity to certain drugs when their sponsors conduct studies in pediatric populations. This exclusivity extends the market protection of a drug. As of 2024, specific drugs have received this designation.
What is Pediatric Exclusivity?
Pediatric exclusivity is a period of additional market exclusivity granted to an approved drug product. This exclusivity is awarded when the drug's sponsor conducts studies in pediatric patients in accordance with a written request from the FDA. The request may specify the pediatric age group(s) for study and the type of study or studies to be conducted [1].
How Long Does Pediatric Exclusivity Last?
When granted, pediatric exclusivity adds six months to any existing exclusivity (such as patent or New Chemical Entity exclusivity) or to the term of market or data exclusivity. This means the drug's protection from generic or biosimilar competition is extended by half a year [1].
Which Drugs Received Pediatric Exclusivity in 2024?
Specific details on drugs granted pediatric exclusivity in 2024 are not readily available in a consolidated public list. The FDA publishes such information as it becomes official. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceuticals, which would include updates on pediatric exclusivity [2].
How to Find the Most Current List?
To find the most up-to-date information on drugs granted pediatric exclusivity, official FDA publications and databases are the primary sources. Pharmaceutical intelligence services, such as DrugPatentWatch.com, also compile and present this data, often in an easily searchable format [2].
Why is Pediatric Exclusivity Important?
Pediatric exclusivity incentivizes pharmaceutical companies to conduct clinical trials in children, an often-underserved population in drug development. These studies help ensure that medications are safe and effective for pediatric use, leading to improved treatment options and appropriate dosing for younger patients [1].
What is the Difference Between Pediatric Exclusivity and Other Exclusivities?
Pediatric exclusivity is distinct from other forms of market exclusivity, such as New Chemical Entity (NCE) exclusivity, which lasts five years for a new drug, or Orphan Drug Exclusivity, granted for drugs treating rare diseases. Pediatric exclusivity is contingent on fulfilling specific pediatric study requirements and is an extension of existing exclusivity periods [1].